FOR IMMEDIATE RELEASE
PRA International Joins Medidata’s ASPire to Win Program
Global CRO Strengthens Longstanding Partnership with EDC Leader to Meet Customer
Demand for Medidata Rave and Offer Sponsors Best-in-Class EDC Technology
NEW YORK, N.Y. and RALEIGH, N.C.– June 20, 2008 – Medidata Solutions, a leading provider of clinical trial solutions, today announced the addition of PRA International, a global clinical research organization, to its ASPire to Win® partnership program. PRA joined the ASPire to Win program to formalize and strengthen its longstanding relationship with Medidata and to further enhance the electronic data capture (EDC) services provided to its clients.
A full-service contract research organization (CRO) with more than 3,500 global employees, PRA International conducts clinical trials in many therapeutic areas with a special emphasis on oncology, central nervous system, allergy/respiratory and cardiovascular disorders. PRA has extensive experience delivering more than 150 EDC trials across six continents and started working with Medidata in 2000 as one of Medidata’s first informal CRO go-to-market partners.
PRA has joined Medidata’s ASPire to Win partnership program, a non-exclusive enablement and accreditation program for CROs and other service providers, in order to leverage the program’s knowledge transfer resources around the Medidata Rave® industry-leading platform for electronic data capture, management and reporting. As an ASPire to Win partner, PRA will broaden its footprint in the sponsor community by adding enhanced Rave-related EDC services to its current EDC platforms and will further support its clients’ needs for comprehensive EDC solutions.
“As the industry searches for the most effective and efficient clinical trials solution, we see that access to timely and correct data will allow data-driven decisions to be made earlier and more accurately in the process,” said Steve Powell, Vice President of Global Data Management at PRA International. “PRA’s commitment to data transparency will complement the leading functionality of the Rave system, and through our expanded partnership, Medidata’s extensive experience will augment our current EDC capabilities to become the premier EDC services company in the business.”
“As CROs continue to serve as a major driver of clinical technology adoption, we are proud to partner with a company that places such strong value on the delivery of best-inclass solutions to sponsors worldwide,” said Graham Bunn, Vice President of Global CRO Partnerships at Medidata Solutions. “We look forward to taking our partnership with PRA to the next level through ASPire to Win and enabling PRA to meet increasing customer demand for Medidata Rave.”
About PRA International
PRA International is a global clinical research organization that provides comprehensive Phase I-IV clinical development services and operates in more than 68 countries across six continents. With more than 30 years of clinical trial experience in multiple therapeutic areas, PRA has core expertise in oncology, CNS, cardiovascular, and allergy/respiratory diseases.
To learn more about PRA International, please visit http://www.prainternational.com or call our world headquarters at +1 (919) 786-8200
About Medidata Solutions Worldwide
Medidata Solutions (www.mdsol.com) is a leading provider of clinical trial solutions that enable the world’s most advanced life science organizations to maximize the value of their clinical research investments by putting powerful tools into researchers’ hands. A pioneer since 1999 in innovative technologies for planning and managing clinical studies – including protocol design; clinical data capture, management and reporting; and trial contracting and negotiation – Medidata Solutions and its global network of business partners address the unique needs of sponsors and sites of all sizes. With deep expertise in conducting studies across all phases and therapeutic areas, on six continents and in
more than 80 countries, Medidata Solutions helps clinical researchers reduce trial cycle times, achieve early visibility to reliable clinical data, and maintain strict fiscal responsibility, while safely accelerating the process of bringing life-enhancing treatments to market.
Contact:
Susan McCarron
Lois Paul & Partners
781.782.5767
Susan_McCarron@lpp.com
Roger Boutin
Lois Paul & Partners PRA International
434.951.3924
BoutinRoger@PRAIntl.com